small molecule

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Active ingredientEMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Strength100MG;150MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.